statistiche ricercatore

Nazione	#
US - Stati Uniti d'America	801
VN - Vietnam	206
SG - Singapore	165
IT - Italia	129
CN - Cina	81
HK - Hong Kong	54
BR - Brasile	48
RU - Federazione Russa	36
DE - Germania	35
SE - Svezia	35
IE - Irlanda	26
GB - Regno Unito	23
FR - Francia	15
ID - Indonesia	13
IN - India	13
CA - Canada	10
AT - Austria	9
BD - Bangladesh	9
DK - Danimarca	8
FI - Finlandia	8
UA - Ucraina	7
ES - Italia	6
AR - Argentina	5
NL - Olanda	5
PH - Filippine	4
SA - Arabia Saudita	4
ZA - Sudafrica	4
CZ - Repubblica Ceca	3
KR - Corea	3
MA - Marocco	3
MX - Messico	3
TR - Turchia	3
AL - Albania	2
AU - Australia	2
EC - Ecuador	2
JP - Giappone	2
KE - Kenya	2
NP - Nepal	2
PE - Perù	2
PL - Polonia	2
UZ - Uzbekistan	2
AZ - Azerbaigian	1
BG - Bulgaria	1
BO - Bolivia	1
BY - Bielorussia	1
CH - Svizzera	1
CL - Cile	1
DZ - Algeria	1
GE - Georgia	1
HN - Honduras	1
HU - Ungheria	1
IL - Israele	1
IQ - Iraq	1
KG - Kirghizistan	1
KW - Kuwait	1
LT - Lituania	1
MN - Mongolia	1
MY - Malesia	1
NZ - Nuova Zelanda	1
PK - Pakistan	1
PY - Paraguay	1
RO - Romania	1
SK - Slovacchia (Repubblica Slovacca)	1
VE - Venezuela	1
Totale	1.815

Nome	#
Specific Expression of a New Bruton Tyrosine Kinase Isoform (p65BTK) in the Glioblastoma Gemistocytic Histotype	550
Multisite analysis of high-grade serous epithelial ovarian cancers identifies genomic regions of focal and recurrent copy number alteration in 3q26.2 and 8q24.3	458
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial	340
Progression after First-Line Cyclin-Dependent Kinase 4/6 Inhibitor Treatment: Analysis of Molecular Mechanisms and Clinical Data	241
High-dose-rate brachytherapy as monotherapy for localized prostate cancer using three different doses - 14 years of single-centre experience	191
Treatment with gefitinib in elderly patients or patients with poor performance status (PS) affected with non small cell lung carcinoma (NSCLC) [Trattamento con Gefitinib nei pazienti anziani o con scarso performance status (PS), affetti da carcinoma polmonare non a piccole cellule (NSCLC)]	131
Totale	1.911

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	44	0	0	0	0	0	0	0	0	0	0	20	24
2021/2022	103	16	18	20	8	0	3	1	6	5	7	8	11
2022/2023	112	9	34	14	12	3	16	6	6	7	0	5	0
2023/2024	93	1	2	6	7	10	21	21	8	4	3	0	10
2024/2025	232	12	21	20	5	14	16	14	7	20	32	29	42
2025/2026	764	185	40	47	62	89	30	146	38	58	64	5	0
Totale													1.911

Bicocca Open Archive